Athira PharmaATHA
About: Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
Employees: 67
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
13% more call options, than puts
Call options by funds: $52K | Put options by funds: $46K
11% less funds holding
Funds holding: 65 [Q2] → 58 (-7) [Q3]
16.0% less ownership
Funds ownership: 57.96% [Q2] → 41.96% (-16.0%) [Q3]
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
88% less capital invested
Capital invested by funds: $58.9M [Q2] → $7.19M (-$51.7M) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Mizuho Graig Suvannavejh 29% 1-year accuracy 7 / 24 met price target | 23%downside $0.50 | Neutral Downgraded | 19 Sept 2024 |
